# US 2020/0270688 A1 · Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0270688 A1
- Document ID: US20200270688A1
- Status: Published application
- Kind: A1
- Application number: 16/720,403
- Filed: 2019-12-19
- Published: 2020-08-27
- Earliest claimed: 2002-12-20
- Assignees: Celera Corporation
- Applicants: Celera Corporation
- Inventors: Olga IAKOUBOVA; James J. DEVLIN; Michele CARGILL
- Web page: https://patentgrep.com/patent/US20200270688A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is based on the discovery of genetic polymorphisms that are associated with myocardial infarction. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

## Claims

### Claim 1

A method of determining whether a human has an altered risk for myocardial infarction, comprising testing nucleic acid from said human for the presence or absence of a polymorphism selected from the group consisting of the polymorphisms at position 101 of any one of the nucleotide sequences of SEQ ID NOS:18,017-73,085 or its complement, wherein the polymorphism indicates an altered risk for myocardial infarction.

### Claim 2 (depends on 1)

The method of claim 1, wherein the polymorphism is selected from the group consisting of the polymorphisms set forth in Tables 6-7.

### Claim 3 (depends on 1)

The method of claim 1, wherein the altered risk is an increased risk.

### Claim 4 (depends on 1)

The method of claim 1, wherein the altered risk is a decreased risk.

### Claim 5 (depends on 1)

The method of claim 1, wherein said human has previously had a myocardial infarction.

### Claim 6 (depends on 1)

The method of claim 1, wherein said nucleic acid is a nucleic acid extract from a biological sample from said human.

### Claim 7 (depends on 6)

The method of claim 6, wherein said biological sample is blood, saliva, or buccal cells.

### Claim 8 (depends on 6)

The method of claim 6, further comprising preparing said nucleic acid extract from said biological sample prior to said testing step.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein said testing step comprises nucleic acid amplification.

### Claim 11 (depends on 10)

The method of claim 10, wherein said nucleic acid amplification is carried out by polymerase chain reaction.

### Claim 12 (depends on 1)

The method of claim 1, further comprising correlating the presence of said polymorphism with an increased risk for myocardial infarction.

### Claim 13 (depends on 12)

The method of claim 12, wherein said correlating step is performed by computer software.

### Claim 14 (depends on 1)

The method of claim 1, further comprising correlating the absence of said polymorphism with a decreased risk for myocardial infarction.

### Claim 15 (depends on 14)

The method of claim 14, wherein said correlating step is performed by computer software.

### Claim 16 (depends on 1)

The method of claim 1, wherein said testing is performed using sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, single-stranded conformation polymorphism analysis, or denaturing gradient gel electrophoresis (DGGE).

### Claim 17 (depends on 1)

The method of claim 1, wherein said testing is performed using an allele-specific method.

### Claim 18 (depends on 17)

The method of claim 17, wherein said allele-specific method is allele-specific probe hybridization, allele-specific primer extension, or allele-specific amplification.

### Claim 19 (depends on 17)

The method of claim 17, wherein said testing is performed using an allele-specific primer provided in Table 5.

### Claim at position 20

20-24. (canceled)

### Claim 25

A method for reducing risk of myocardial infarction in a human, the method comprising administering to said human an effective amount of a therapeutic agent, said human having been identified as having an increased risk for myocardial infarction due to the presence or absence of a polymorphism selected from the group consisting of the polymorphisms at position 101 of any one of the nucleotide sequences of SEQ ID NOS:18,017-73,085 or its complement.

### Claim 26 (depends on 25)

The method of claim 25, wherein the method comprises testing nucleic acid from said human for the presence or absence of said polymorphism.

### Claim at position 23

27-28. (canceled)
